PMID- 28691910
OWN - NLM
STAT- MEDLINE
DCOM- 20180802
LR  - 20201218
IS  - 1969-6213 (Electronic)
IS  - 1774-024X (Linking)
VI  - 13
IP  - 10
DP  - 2017 Nov 20
TI  - Transcatheter aortic valve implantation for mixed versus pure stenotic aortic 
      valve disease.
PG  - 1157-1165
LID - EIJ-D-17-00328 [pii]
LID - 10.4244/EIJ-D-17-00328 [doi]
AB  - AIMS: In addition to patients with pure/predominant aortic stenosis (PAS), 
      real-world transcatheter aortic valve implantation (TAVI) referrals include 
      patients with mixed aortic valve disease (MAVD; severe stenosis+moderate-severe 
      regurgitation). We sought to compare TAVI outcomes in patients with MAVD vs. PAS. 
      METHODS AND RESULTS: Out of 793 consecutive patients undergoing TAVI, 106 (13.4%) 
      had MAVD. Patients with MAVD were younger and had a higher operative risk, a more 
      severe adverse cardiac remodelling, and a worse functional status than patients 
      with PAS. Moderate-severe prosthetic valve regurgitation (PVR) was significantly 
      more frequent in patients with MAVD than in patients with PAS (15.7% vs. 3.6%, 
      p=0.003), even after propensity-score and multivariable adjustments. 
      Moderate-severe PVR was associated with increased one-year mortality in patients 
      with PAS (log-rank p=0.002), but not in patients with MAVD (log-rank p=0.27). 
      Eventually, all-cause and cardiac mortality as well as the functional capacity 
      were similar in the two study groups up to one year. CONCLUSIONS: A significant 
      proportion of patients referred for TAVI in a real-world registry has MAVD. 
      Moderate-severe AR at baseline can influence the rate and modify the clinical 
      sequelae of post-TAVI PVR. Eventually, clinical outcomes in patients with MAVD 
      are comparable to those in patients with PAS in the acute and midterm phases, in 
      spite of a baseline higher risk. MAVD should not be considered a contraindication 
      for TAVI.
FAU - Abdelghani, Mohammad
AU  - Abdelghani M
AD  - Department of Cardiology, Academic Medical Center, Amsterdam, the Netherlands.
FAU - Cavalcante, Rafael
AU  - Cavalcante R
FAU - Miyazaki, Yosuke
AU  - Miyazaki Y
FAU - de Winter, Robbert J
AU  - de Winter RJ
FAU - Tijssen, Jan G
AU  - Tijssen JG
FAU - Sarmento-Leite, Rogerio
AU  - Sarmento-Leite R
FAU - Mangione, Jose A
AU  - Mangione JA
FAU - Abizaid, Alexandre
AU  - Abizaid A
FAU - Lemos, Pedro A
AU  - Lemos PA
FAU - Serruys, Patrick W
AU  - Serruys PW
FAU - de Brito, Fabio S Jr
AU  - de Brito FS Jr
LA  - eng
PT  - Journal Article
PL  - France
TA  - EuroIntervention
JT  - EuroIntervention : journal of EuroPCR in collaboration with the Working Group on 
      Interventional Cardiology of the European Society of Cardiology
JID - 101251040
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Aortic Valve/surgery
MH  - Aortic Valve Stenosis/*surgery
MH  - Bicuspid Aortic Valve Disease
MH  - Cardiac Catheterization/methods
MH  - Female
MH  - Heart Defects, Congenital/*surgery
MH  - Heart Valve Diseases/*surgery
MH  - Heart Valve Prosthesis/adverse effects
MH  - Heart Valve Prosthesis Implantation/methods
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Risk Factors
MH  - *Transcatheter Aortic Valve Replacement/adverse effects
MH  - Treatment Outcome
EDAT- 2017/07/12 06:00
MHDA- 2018/08/03 06:00
CRDT- 2017/07/11 06:00
PHST- 2017/07/12 06:00 [pubmed]
PHST- 2018/08/03 06:00 [medline]
PHST- 2017/07/11 06:00 [entrez]
AID - EIJ-D-17-00328 [pii]
AID - 10.4244/EIJ-D-17-00328 [doi]
PST - ppublish
SO  - EuroIntervention. 2017 Nov 20;13(10):1157-1165. doi: 10.4244/EIJ-D-17-00328.